AU2525601A - Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof - Google Patents

Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof

Info

Publication number
AU2525601A
AU2525601A AU25256/01A AU2525601A AU2525601A AU 2525601 A AU2525601 A AU 2525601A AU 25256/01 A AU25256/01 A AU 25256/01A AU 2525601 A AU2525601 A AU 2525601A AU 2525601 A AU2525601 A AU 2525601A
Authority
AU
Australia
Prior art keywords
gel
suspension
composition
solution
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25256/01A
Other languages
English (en)
Inventor
Jack Auzerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INVESTIGATIONS THERAPEUTIQUES ESSAIS CLINIQUES SERVICES
Original Assignee
INVEST S THERAPEUTIQUES ESSAIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INVEST S THERAPEUTIQUES ESSAIS filed Critical INVEST S THERAPEUTIQUES ESSAIS
Publication of AU2525601A publication Critical patent/AU2525601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
AU25256/01A 1999-12-14 2000-12-14 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof Abandoned AU2525601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915763A FR2802097B1 (fr) 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
FR9915763 1999-12-14
PCT/FR2000/003533 WO2001043720A1 (fr) 1999-12-14 2000-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication

Publications (1)

Publication Number Publication Date
AU2525601A true AU2525601A (en) 2001-06-25

Family

ID=9553244

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25256/01A Abandoned AU2525601A (en) 1999-12-14 2000-12-14 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof

Country Status (13)

Country Link
US (1) US20030091642A1 (https=)
EP (1) EP1237537B1 (https=)
JP (1) JP2003516957A (https=)
AT (1) ATE336987T1 (https=)
AU (1) AU2525601A (https=)
CA (1) CA2394416A1 (https=)
CY (1) CY1106249T1 (https=)
DE (1) DE60030319T2 (https=)
DK (1) DK1237537T3 (https=)
ES (1) ES2270895T3 (https=)
FR (1) FR2802097B1 (https=)
PT (1) PT1237537E (https=)
WO (1) WO2001043720A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2004274000B2 (en) * 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
CN101374501A (zh) * 2006-01-05 2009-02-25 药物技术公司 组合物及其使用方法
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
JP2533723B2 (ja) * 1992-12-28 1996-09-11 東興薬品工業株式会社 速乾性ゲルタイプ手指消毒剤
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5902110A (en) * 1995-12-18 1999-05-11 The Block Drug Company Bone regeneration
US5869601A (en) * 1996-04-05 1999-02-09 S. C. Johnson & Son, Inc. Method of stabilizing the viscosity of a thickened composition
EP1011609A4 (en) * 1997-05-09 2000-08-16 Medlogic Global Corp COMPOSITIONS FOR COSMETIC APPLICATIONS
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations

Also Published As

Publication number Publication date
ES2270895T3 (es) 2007-04-16
CA2394416A1 (fr) 2001-06-21
PT1237537E (pt) 2007-01-31
DE60030319T2 (de) 2007-08-30
EP1237537B1 (fr) 2006-08-23
FR2802097B1 (fr) 2002-12-13
ATE336987T1 (de) 2006-09-15
FR2802097A1 (fr) 2001-06-15
DK1237537T3 (da) 2006-12-27
JP2003516957A (ja) 2003-05-20
EP1237537A1 (fr) 2002-09-11
US20030091642A1 (en) 2003-05-15
WO2001043720A1 (fr) 2001-06-21
CY1106249T1 (el) 2011-06-08
DE60030319D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU6825300A (en) Compounds
EP0679390A3 (en) Sprayable topical pharmaceutical compositions
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU6529796A (en) Biological agent compositions
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
AU3674500A (en) L-amino acid-producing bacteria and process for producing l-amino acid
AU5850200A (en) Positive plate active material, method for producing the same, and secondary cell
AU6559800A (en) Use of hyaluronic acid derivatives in pharmaceutical preparations and biomaterials for the prevention and treatment of cutaneous scars
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2002366467A1 (en) Diffusion film, electrode having the diffusion film, and process for producing diffusion film
AU6100194A (en) Active drug delivery device, electrode, and method for making same
AU2001253297A1 (en) Sterilization process for air, liquid and surfaces
AU3366899A (en) Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
AU2525601A (en) Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof
AU7552098A (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
AU1811695A (en) Antitussive composition containing an antitussive and benzydamine
AU2537695A (en) Epoxysuccinic acid derivatives, their production and use
AU3343899A (en) 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient
AU8004798A (en) Injectable, biocompatible, hydrophilic gel, process for its preparation and application
WO2000069841A3 (en) Benzofuranylaminoalcohols
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
AU3068600A (en) Printing process combining conventional and braille printing with the aid of an offset-type printing machine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase